tiprankstipranks
Trending News
More News >
Imagion Biosystems Ltd. (AU:IBX)
ASX:IBX
Australian Market

Imagion Biosystems Ltd. (IBX) AI Stock Analysis

Compare
8 Followers

Top Page

AU

Imagion Biosystems Ltd.

(Sydney:IBX)

Rating:42Neutral
Price Target:
AU$0.00
▼(-100.00%Downside)
The overall stock score reflects the significant financial challenges faced by Imagion Biosystems Ltd., including negative equity and cash flow issues. Technical analysis further indicates bearish momentum, and valuation metrics highlight concerns over profitability. These factors combine to create a low overall score.

Imagion Biosystems Ltd. (IBX) vs. iShares MSCI Australia ETF (EWA)

Imagion Biosystems Ltd. Business Overview & Revenue Model

Company DescriptionImagion Biosystems Limited provides medical imaging technologies based on superparamagnetic relaxometry for cancer and disease detection, and monitoring therapy. It has activities in nanotechnology; biotechnology; cancer diagnostics; and superparamagnetic relaxometry. The company develops MagSense, which is in Phase I clinical trials for the treatment of HER2 breast cancers; and PrecisionMRX, an iron oxide nanoparticle to detect cancer. Imagion Biosystems Limited has a collaborative research program with Patrys Limited to use the combined technologies for enhancing brain tumor imaging and diagnosis; and a joint development agreement with Global Cancer Technology, Inc. to develop GCT's novel nanoscintillator technology for the treatment of breast cancer. The company was incorporated in 2016 and is based in San Diego, California.
How the Company Makes MoneyImagion Biosystems makes money primarily through the development and commercialization of its MagSense™ technology. The company generates revenue by partnering with healthcare institutions, research organizations, and pharmaceutical companies to integrate its imaging solutions into clinical and research settings. Revenue streams include licensing agreements, collaboration fees, and potential sales of diagnostic imaging products. The company may also receive funding through grants and strategic partnerships that support the research and development of its diagnostic technologies. Additionally, Imagion Biosystems may pursue revenue through the commercialization of future products and applications derived from its core technology.

Imagion Biosystems Ltd. Financial Statement Overview

Summary
Imagion Biosystems Ltd. shows strong revenue growth but faces profitability and financial stability challenges. Negative equity and high leverage pose significant risks, while negative cash flows indicate sustainability concerns.
Income Statement
45
Neutral
The company shows substantial revenue growth, with a 94.9% increase from the previous period, indicating strong top-line expansion. However, persistent negative net income and EBIT margins suggest ongoing challenges in achieving profitability. The gross profit margin has improved significantly but remains under pressure, indicating cost management issues.
Balance Sheet
30
Negative
The balance sheet reveals a concerning negative equity position, indicating financial instability. High debt levels relative to equity suggest significant leverage risks. Despite these issues, the company has managed to maintain cash reserves, albeit declining over time, reflecting potential liquidity challenges.
Cash Flow
40
Negative
Operating cash flow remains negative, highlighting difficulties in generating cash from core operations. While there is a notable improvement in free cash flow, it still remains negative, reflecting ongoing cash burn. The reliance on financing cash flows to sustain operations indicates potential sustainability issues.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue2.67M1.37M473.43K232.87K205.72K
Gross Profit2.26M-3.88M-3.14M-2.47M-2.66M
EBITDA-700.09K-10.30M-9.49M-5.90M-5.19M
Net Income-2.07M-12.47M-9.81M-8.64M-7.80M
Balance Sheet
Total Assets2.80M4.59M9.98M14.12M14.12M
Cash, Cash Equivalents and Short-Term Investments2.67M227.08K4.45M13.39M13.20M
Total Debt2.85M6.04M4.60M46.02K660.98K
Total Liabilities5.09M8.37M5.30M809.88K1.21M
Stockholders Equity-2.28M-3.79M4.68M13.31M12.91M
Cash Flow
Free Cash Flow-1.27M-8.51M-9.21M-5.29M-4.63M
Operating Cash Flow-1.27M-8.32M-8.70M-5.07M-4.62M
Investing Cash Flow83.74K-190.38K-468.73K-310.09K-7.86K
Financing Cash Flow3.61M4.29M-962.06K5.15M14.52M

Imagion Biosystems Ltd. Technical Analysis

Technical Analysis Sentiment
Negative
Last Price0.01
Price Trends
50DMA
<0.01
Positive
100DMA
0.01
Negative
200DMA
0.02
Negative
Market Momentum
MACD
>-0.01
Negative
RSI
21.16
Positive
STOCH
-50.00
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:IBX, the sentiment is Negative. The current price of 0.01 is below the 20-day moving average (MA) of 0.01, above the 50-day MA of <0.01, and below the 200-day MA of 0.02, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 21.16 is Positive, neither overbought nor oversold. The STOCH value of -50.00 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:IBX.

Imagion Biosystems Ltd. Peers Comparison

Overall Rating
UnderperformOutperform
Sector (49)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
AUCTE
69
Neutral
AU$36.36M19.8787.09%2.68%1.86%16.10%
49
Neutral
AU$2.53B3.19-57.47%2.77%36.73%13.67%
AUBDX
46
Neutral
AU$24.15M-104.23%-17.26%
AULDX
43
Neutral
AU$20.96M-51.49%80.84%57.59%
AUIBX
42
Neutral
AU$2.21M
55.07%88.20%
AUWFL
AU$1.48M
AUIIQ
43
Neutral
AU$41.30M-39.07%26.07%0.85%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
AU:IBX
Imagion Biosystems Ltd.
0.01
-0.07
-87.50%
AU:BDX
BCAL Diagnostics Limited
0.07
-0.07
-50.00%
AU:LDX
Lumos Diagnostics Holdings Ltd.
0.03
-0.01
-25.00%
AU:CTE
Cryosite Limited
0.74
-0.36
-32.73%
AU:WFL
Wellfully Limited
0.01
0.00
0.00%
AU:IIQ
Inoviq Ltd
0.36
-0.20
-35.71%

Imagion Biosystems Ltd. Corporate Events

Imagion Biosystems to Present at Landmark Venture Forum
Jun 12, 2025

Imagion Biosystems announced its participation in the Landmark Venture Forum, a prestigious event limited to select investors and guests. The company’s Chief Business Officer, Ward Detwiler, will present on their groundbreaking molecular magnetic resonance imaging technology, which could significantly impact the early detection of cancer, potentially improving Imagion’s industry positioning and offering promising implications for stakeholders.

Imagion Biosystems Relocates Office to Enhance Operations
Jun 2, 2025

Imagion Biosystems has announced a change in its registered office and principal place of business to a new address in Melbourne, while maintaining the same contact details. This move signifies a strategic step in its operations, potentially enhancing its business functions and stakeholder engagement.

Imagion Biosystems Ltd. AGM Results: All Resolutions Carried
May 30, 2025

Imagion Biosystems Ltd. announced the results of its Annual General Meeting held on May 30, 2025, where all resolutions were carried. Key resolutions included the adoption of the remuneration report, re-election of Brett Mitchell as a director, and the approval of options issuance to key personnel and entities. The successful passage of these resolutions reflects shareholder support for the company’s strategic direction and governance, potentially strengthening its market position and operational capabilities.

Imagion Biosystems Advances Cancer Detection Programs
May 28, 2025

Imagion Biosystems has provided a business update ahead of its Annual General Meeting, highlighting the progress of its MagSense® HER2 Imaging Agent for HER2+ breast cancer. The company plans to begin manufacturing the imaging agent in June and aims to file an Investigational New Drug application with the FDA for a Phase 2 study in the third quarter of 2025. The company has engaged with the FDA for feedback and identified a Principal Investigator for the study. Additionally, Imagion is optimizing MRI protocols in collaboration with Siemens and Wayne State University. The company is also preparing to restart its prostate and ovarian cancer programs, with Dr. Kayat-Bittencourt joining as a clinical advisor for the prostate cancer program.

Imagion Biosystems to Hold Virtual AGM on May 30, 2025
May 1, 2025

Imagion Biosystems Limited has announced that its Annual General Meeting (AGM) will be held virtually on May 30, 2025. Shareholders are encouraged to access meeting materials online and submit their proxy votes ahead of the meeting. The virtual format allows shareholders to participate by asking questions and voting on resolutions, ensuring engagement despite the lack of a physical gathering.

Imagion Biosystems Advances Cancer Imaging Program with Upcoming IND Filing
Apr 30, 2025

Imagion Biosystems has released its quarterly activity report for Q1 FY2025, highlighting progress in its MagSense® HER2 breast cancer imaging agent program. The company is preparing to file an Investigational New Drug (IND) application with the U.S. FDA, which would enable the next phase of clinical studies. Manufacturing of the imaging agent is underway, and discussions with leading hospitals and cancer centers in the U.S. are ongoing. The company expects to file the IND in the third quarter and begin the Phase 2 study in the latter half of the year. Additionally, research and development for prostate and ovarian cancer programs are anticipated to commence later in the year, contingent on funding. The company reported a cash balance of AU$1.71 million at the end of March 2025, with increased operating cash outflows due to R&D expenditures.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jun 28, 2025